Literature DB >> 26658418

Multiple Myeloma Gets Three New Drugs.

Alissa Poh.   

Abstract

In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26658418     DOI： 10.1158/2159-8290.CD-NB2015-169

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  4 in total

1.  Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.

Authors:  X Leleu; C Kyriakou; I Vande Broek; P Murphy; P Bacon; P Lewis; H Gilet; B Arnould; M T Petrucci
Journal:  Blood Cancer J       Date:  2017-03-17       Impact factor: 11.037

2.  A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021.

Authors:  Hanyi Ding; Xiaoyuan Zhang; Dongxu Gang; Xiaoyu He; Songfu Jiang
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 1.241

3.  The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences.

Authors:  Cheryl Pritlove; Mobin Jassi; Bridget Burns; Arleigh McCurdy
Journal:  BMC Cancer       Date:  2021-07-08       Impact factor: 4.430

4.  Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review.

Authors:  Muhammad Husnain; Sandra Kurtin; Nikki Barkett; Irbaz Bin Riaz; Amit Agarwal
Journal:  Case Rep Oncol Med       Date:  2016-09-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.